Deals in Depth: March 2008
March 2008 dealmaking highlights: Datascope exits the patient monitoring business with a sale to Mindray for $202mm; Teva makes an important leap into Spanish generics through its $337mm Bentley Pharmaceuticals buy; and private financings in biopharma companies again overtake public sector investments, accounting for $797mm versus $5mm from only one follow-on public offering.
You may also be interested in...
Every medical device company is asking, "How can we take advantage of emerging opportunities in China?" Given the country's economic and population booms--China is home to one fifth the world's population--many analysts expect its medical device market to shortly come into full bloom, enjoying a compound annual growth rate of 15% over the next 10 years from a base of approximately $10 billion in 2007. Fueling this growth are positive improvements in China's business climate, making China a much less risky place to do business. Multinational firms are forming alliances in China to help them reach an untapped 1.3 billion patient population, even as a new breed of venture capital-backed, Western-style Chinese companies begins to grab a home court advantage.
A “federated” training method could be used to reduce bias in AI, according to one expert on patient safety.
Pandemic Perspectives: Acacia CEO Says Pre-Existing Commercial Relationships, End-User Backing Key To Product Launches
Despite sector lockdowns there, Acacia has just launched two hospital-based products in the US. Its CEO Mike Bolinder tells Scrip how it defied the pandemic to get its drugs to their users.